<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="664">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271555</url>
  </required_header>
  <id_info>
    <org_study_id>Inonu 3</org_study_id>
    <nct_id>NCT02271555</nct_id>
  </id_info>
  <brief_title>The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy</brief_title>
  <official_title>Inonu University, Turgut Ozal Medical Center, Department of Anesthesiology and Reanimation Malatya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be evaluated the effects of a single loading dose of remifentanil
      (1µg/kg), administered as an adjunct to sevoflurane, on duration of hemodynamic profile,
      seizure activity, and recovery times during electroconvulsive therapy (ECT) in patients with
      major depression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive patients will enrolled this trial. Mean arterial pressure (MAP) and heart
      rate (HR) and peripheral oxygen saturation values will be recorded prior to anesthetic
      induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 minute after the
      seizure have ended (T3, T4, T5, and T6, respectively). The peak heart rate during the
      seizure will be recorded from the Electrocardiogram.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The effects of remifentanil on the heart rate after electroconvulsive therapy</measure>
    <time_frame>20 minute</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 minute after the seizure have ended (T3, T4, T5, and T6, respectively).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure duration</measure>
    <time_frame>20 minute</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>During electroconvulsive therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effects of remifentanil on the mean arterial pressure after electroconvulsive therapy</measure>
    <time_frame>20 minute</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 minute after the seizure have ended (T3, T4, T5, and T6, respectively).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Haemodynamic Rebound</condition>
  <arm_group>
    <arm_group_label>sevoflurane-remifentanil (Group SR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane-saline (Group SS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Anesthetic induction will be achieved via 8% sevoflurane</description>
    <arm_group_label>sevoflurane-remifentanil (Group SR)</arm_group_label>
    <arm_group_label>sevoflurane-saline (Group SS)</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.</description>
    <arm_group_label>sevoflurane-remifentanil (Group SR)</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.</description>
    <arm_group_label>sevoflurane-saline (Group SS)</arm_group_label>
    <other_name>0.9% isotonic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive patients

        Exclusion Criteria:

          -  younger than 18 years, pregnant, had a history of myocardial infarction in the
             previous six months, atrial fibrillation or flutter, heart block, unregulated
             hypertension, cerebrovascular diseases, known drug allergy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feray Erdil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>İnonu Univercity Medical Faculty Department of Anestheisology and Reanimation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feray Erdil, MD</last_name>
    <phone>+90 422 341 06 60</phone>
    <phone_ext>3148</phone_ext>
    <email>feray.erdil@inonu.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmut Durmus, MD</last_name>
    <phone>+90 422 341 06 60</phone>
    <phone_ext>3105</phone_ext>
    <email>mahmut.durmus@inonu.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turgut Ozal Medical Center</name>
      <address>
        <city>Malatya</city>
        <zip>44315</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Nishikawa K, Higuchi M, Kawagishi T, Shimodate Y, Yamakage M. Effect of divided supplementation of remifentanil on seizure duration and hemodynamic responses during electroconvulsive therapy under propofol anesthesia. J Anesth. 2011 Feb;25(1):29-33. doi: 10.1007/s00540-010-1049-4. Epub 2010 Nov 30.</citation>
    <PMID>21116659</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 20, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Feray Erdil</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <keyword>electroconvulsive therapy</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>remifentanil</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
